Clinical use of proton-pump inhibitors but not H₂-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population

References

• Schubert ML. Gastric secretion. Curr Opin Gastroenterol 2004; 20: 519–25
   PubMed Web of Science ®Google Scholar
• Modlin IM, Kidd M, Marks IN, Tang LH. The pivotal role of John S. Edkins in the discovery of gastrin. World J Surg 1997; 21: 226–34
   PubMed Web of Science ®Google Scholar
• Dockray GJ. Topical review. Gastrin and gastric epithelial physiology. J Physiol 1999; 518: 315–24
   PubMed Web of Science ®Google Scholar
• Goetze JP, Paloheimo LI, Linnala A, Sipponen P, Hansen CP, Rehfeld JF. Gastrin-17 specific antibodies are too specific for gastrinoma diagnosis but stain G-cells. Scand J Gastroenterol 2005; 40: 596–8
   PubMed Web of Science ®Google Scholar
• Bakke I, Qvigstad G, Brenna E, Sandvik AK, Waldum HL. Gastrin has a specific proliferative effect on the rat enterochromaffin-like cell, but not on the parietal cell: a study by elutriation centrifugation. Acta Physiol Scand 2000; 169: 29–37
   PubMedGoogle Scholar
• Ohning GV, Wong HC, Lloyd KC, Walsh JH. Gastrin mediates the gastric mucosal proliferative response to feeding. Am J Physiol 1996; 271: G470–6
   PubMed Web of Science ®Google Scholar
• Seva C, Dickson CJ, Yamada T. Growth-promoting effects of glycine-extended progastrin. Science 1994; 265: 410–2
   PubMed Web of Science ®Google Scholar
• FitzGerald AJ, Ghatei MA, Mandir N, Bloom SR, Iversen L, Goodlad RA. Effects of amidated gastrin and glycine-extended gastrin on cell proliferation and crypt fission in parenterally and orally fed rats. Digestion 2002; 66: 58–66
   PubMed Web of Science ®Google Scholar
• Cui GL, Sandvik AK, Munkvold B, Waldum HL. Glycine-extended gastrin-17 stimulates acid secretion only via CCK-2 receptor-induced histamine release in the totally isolated vascularly perfused rat stomach. Acta Physiol Scand 2002; 174: 125–30
   PubMedGoogle Scholar
• Waldum HL, Fossmark R, Bakke I, Martinsen TC, Qvigstad G. Hypergastrinemia in animals and man: causes and consequences. Scand J Gastroenterol 2004; 39: 505–9
   PubMed Web of Science ®Google Scholar
• Hersey SJ, May D, Schyberg D. Stimulation of pepsinogen release from isolated gastric glands by cholecystokinin-like peptides. Am J Physiol 1983; 244: G192–7
   PubMed Web of Science ®Google Scholar
• Waldum HL, Burhol PG, Straume BK. Serum group I pepsinogens during prolonged infusion of pentagastrin and secretin in man. Scand J Gastroenterol 1979; 14: 761–8
   PubMed Web of Science ®Google Scholar
• Ten Kate RW, Tuynman HA, Festen HP, Pals G, Meuwissen SG. Effect of high dose omeprazole on gastric pepsin secretion and serum pepsinogen levels in man. Eur J Clin Pharmacol 1988; 35: 173–6
   PubMed Web of Science ®Google Scholar
• Corbett ME, Boyd EJ, Penston JG, Wormsley KG, Watt PW, Rennie MJ. Pentagastrin increases pepsin secretion without increasing its fractional synthetic rate. Am J Physiol 1995; 269: E418–25
   PubMed Web of Science ®Google Scholar
• Gillen D, Wirz AA, Ardill JE, McColl KE. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 1999; 116: 239–47
   PubMed Web of Science ®Google Scholar
• Qvigstad G, Waldum H. Rebound hypersecretion after inhibition of gastric acid secretion. Basic Clin Pharmacol Toxicol 2004; 94: 202–8
   PubMed Web of Science ®Google Scholar
• Festen HP, Thijs JC, Lamers CB, Jansen JM, Pals G, Frants RR, et al. Effect of oral omeprazole on serum gastrin and serum pepsinogen I levels. Gastroenterology 1984; 87: 1030–4
   PubMed Web of Science ®Google Scholar
• Iwao T, Toyonaga A, Kuboyama S, Tanikawa K. Effects of omeprazole and lansoprazole on fasting and postprandial serum gastrin and serum pepsinogen A and C. Hepatogastroenterology 1995; 42: 677–82
   PubMedGoogle Scholar
• Brunner G, Hell M, Hengels KJ, Hennig U, Fuchs W. Influence of lansoprazole on intragastric 24-hour pH, meal-stimulated gastric acid secretion, and concentrations of gastrointestinal hormones and enzymes in serum and gastric juice in healthy volunteers. Digestion 1995; 56: 137–44
   PubMed Web of Science ®Google Scholar
• Schumann, KM, Massarrat, S. Changes in total pepsin activity and pepsinogen I in human sera under stimulation and inhibition of gastric acid secretion. Hepatogastroenterology 1991;38(Suppl 1):33–6.
   PubMedGoogle Scholar
• Stoschus B, Hamscher G, Ikonomou S, Partoulas G, Eberle C, Sauerbruch T, et al. Effect of omeprazole treatment on plasma concentrations of the gastric peptides, xenin, gastrin and somatostatin, and of pepsinogen. J Pept Res 1998; 52: 27–33
   PubMedGoogle Scholar
• Fraser AG, Lam WM, Luk YW, Sercombe J, Sawyerr AM, Hudson M, et al. Effect of ranitidine bismuth citrate on postprandial plasma gastrin and pepsinogens. Gut 1993; 34: 338–42
   PubMed Web of Science ®Google Scholar
• Ohsawa T, Hirata W, Higichi S. Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level. Int J Clin Pharmacol Res 2002; 22: 29–35
   PubMedGoogle Scholar
• Lazzaroni M, Sangaletti O, Bianchi Porro G. Gastric acid secretion and plasma gastrin during short-term treatment with omeprazole and ranitidine in duodenal ulcer patients. Hepatogastroenterology 1992; 39: 366–70
   PubMedGoogle Scholar
• Sanduleanu S, Stridsberg M, Jonkers D, Hameeteman W, Biemond I, Lundqvist G, et al. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther 1999; 13: 145–53
   PubMed Web of Science ®Google Scholar
• Aro P, Ronkainen J, Storskrubb T, Bolling-Sternevald E, Carlsson R, Johansson SE, et al. Valid symptom reporting at upper endoscopy in a random sample of the Swedish adult general population: the Kalixanda study. Scand J Gastroenterol 2004; 39: 1280–8
   PubMed Web of Science ®Google Scholar
• Storskrubb T, Aro P, Ronkainen J, Sipponen P, Nyhlin H, Talley NJ, et al. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: the Kalixanda study. Scand J Gastroenterol 2008; 43: 1–8
   Web of Science ®Google Scholar
• Väänänen H, Vauhkonen M, Helske T, Kaariainen I, Rasmussen M. Tunturi-Hihnala H, et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol 2003; 15: 885–91
   PubMed Web of Science ®Google Scholar
• Kikuchi S, Inaba Y, Wada O, Miki K, Tenjin H, Kaneko E, et al. The association of smoking and drinking habits with serum pepsinogens. Int J Epidemiol 1995; 24: 346–53
   PubMed Web of Science ®Google Scholar
• Lamers CB, Rotter JI, Jansen JB, Samloff IM. Serum pepsinogen I in familial multiple endocrine neoplasia type I. Dig Dis Sci 1988; 33: 1274–6
   PubMed Web of Science ®Google Scholar
• Biemond I, Kreuning J, Jansen JB, Lamers CB. Serum pepsinogens in patients with gastric diseases or after gastric surgery. Scand J Gastroenterol 1994; 29: 238–42
   PubMed Web of Science ®Google Scholar
• Lamberts R, Brunner G, Solcia E. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion 2001; 64: 205–13
   PubMed Web of Science ®Google Scholar
• Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996; 39: 649–53
   PubMed Web of Science ®Google Scholar
• Niklasson, A, Lindström, L, Simren, M, Lindberg, G, Bjørnsson, E. Dyspeptic symptoms development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Gastroenterology 2008;134(Suppl 1):A 112.
   Google Scholar
• Sharma B, Axelson M, Pounder RP, Lundborg P, Öhman M, Santana A, et al. Acid secretory capacity and plasma gastrin concentration after administration of omeprazole to normal subjects. Aliment Pharmacol Ther 1987; 1: 67–76
   PubMedGoogle Scholar
• Prewett EJ, Hudson M, Nwokolo CU, Sawyerr AM, Pounder RE. Nocturnal intragastric acidity during and after a period of dosing with either ranitidine or omeprazole. Gastroenterology 1991; 100: 873–7
   PubMed Web of Science ®Google Scholar
• Orr WC, Mellow MH, Grossman MR. Patterns of 24-hour oesophageal acid exposure after acute withdrawal of acid suppression. Aliment Pharmacol Ther 1995; 9: 571–4
   PubMed Web of Science ®Google Scholar
• Bell N, Karol MD, Sachs G, Greski-Rose P, Jennings DE, Hunt RH. Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers. Aliment Pharmacol Ther. 2001; 15: 105–13
   PubMed Web of Science ®Google Scholar
• Sharma BK, Walt RP, Pounder RE, Gomes MD, Wood EC, Logan LH. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut. 1984; 25: 957–64
   PubMed Web of Science ®Google Scholar
• Storskrubb T, Aro P, Ronkainen J, Vieth M, Stolte M, Wreiber K, et al. A negative Helicobacter pylori serology test is more reliable for exclusion of premalignant gastric conditions than a negative test for current H. pylori infection: a report on histology and H. pylori detection in the general adult population. Scand J Gastroenterol 2005; 40: 302–11
   PubMed Web of Science ®Google Scholar
• Agréus L, Engstrand L, Svärdsudd K, Nyrén O, Tibblin G. Helicobacter pylori seropositivity among Swedish adults with and without abdominal symptoms. A population-based epidemiologic study. Scand J Gastroenterol 1995; 30: 752–7
   PubMed Web of Science ®Google Scholar
• The EUROGAST Study Group. Epidemiology of, and risk factors for, Helicobacter pylori infection among 3194 asymptomatic subjects in 17 populations. Gut 1993;34:1672–6.
   PubMed Web of Science ®Google Scholar